Capital, Llclewis Joseph Bo... Net Worth

The estimated Net Worth of Capital, Llclewis Joseph Bo... is at least $25.6 Million dollars as of 6 January 2017. Capital Bo owns over 286,163 units of Mirati Therapeutics Inc stock worth over $25,560,563 and over the last 8 years Capital sold MRTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Bo MRTX stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Mirati Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital bought 286,163 units of MRTX stock worth $1,602,513 on 6 January 2017.

The largest trade Capital's ever made was buying 286,163 units of Mirati Therapeutics Inc stock on 6 January 2017 worth over $1,602,513. On average, Capital trades about 286,163 units every 0 days since 2017. As of 6 January 2017 Capital still owns at least 435,444 units of Mirati Therapeutics Inc stock.

You can see the complete history of Capital Bo stock trades at the bottom of the page.

Insiders trading at Mirati Therapeutics Inc

Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza..., and Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.

What does Mirati Therapeutics Inc do?

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.

Complete history of Capital Bo stock trades at Mirati Therapeutics Inc

Mirati Therapeutics Inc executives and stock owners

Mirati Therapeutics Inc executives and other stock owners filed with the SEC include:

• Charles Baum,
  President, Chief Executive Officer, Director
• James Christensen,
  Executive Vice President, Chief Scientific Officer
• Faheem Hasnain,
  Chairman of the Board
• Julie Cherrington,
  Independent Director
• Dr. Charles M. Baum M.D., Ph.D.,
  Founder, Pres, Head of R&D and Director
• Dr. James G. Christensen Ph.D.,
  Chief Scientific Officer
• Benjamin J. Hickey M.B.A.,
  Chief Commercial Officer
• Bruce Carter,
  Independent Director
• Craig Johnson,
  Independent Director
• Henry Fuchs,
  Independent Director
• Maya Martinez-Davis,
  Independent Director
• Michael Grey,
  Independent Director
• Aaron Davis,
  Independent Director
• Temre Johnson,
  Director, Investor Relations and Corporate Communications
• Joseph Leveque,
  Chief Medical Officer
• Benjamin Hickey,
  Executive Vice President, Chief Commercial Officer
• Daniel Faga,
  Chief Operating Officer, Executive Vice President
• Michael E. Paolucci,
  Chief People Officer
• Laurie D. Stelzer,
  Chief Financial Officer
• Ryan Asay,
  VP & Head of Corp. Affairs
• Dr. Kelly Covello Ph.D.,
  VP & Head of Medical Affairs
• Kristin Gustafson,
  Chief HR Officer
• Reena R. Desai,
  Gen. Counsel & Corp. Sec.
• Vickie S. Reed,
  Sr. VP & Chief Accounting Officer
• David D. Meek,
  CEO & Director
• Rodney W Lappe,
  Director
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer,
  10% owner
• Asset Management Inc. Boxer,
  10% owner
• Mark J Gergen,
  Exec. VP and COO
• Ltd. Braslyn,
  10% owner
• William R Ringo,
  Director
• Christopher C. Lemasters,
  EVP, Chief Business Officer
• Laurie Stelzer,
  Chief Financial Officer
• Capital, Llc Boxer Asset Ma...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Capital Advisors Llc Aghaza...,
  
• Capital, Llc Braslyn Ltd. B...,
  
• Healthcare Master Fund Ltd ...,
  
• Thirteen Inc. Tuesday,
  10% owner
• Capital, Llc Boxer Asset Ma...,
  
• Maria E Martinez,
  
• Neil Reisman,
  10% owner
• Investors, Llc Mva,
  10% owner
• Shehan Bharatha Dissanayake,
  10% owner
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Capital Management Ltd.Bras...,
  
• Capital Partners Lptang Kev...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Martin Godbout,
  Director
• Jamie A Donadio,
  VP of Finance
• Advisors Llc Orbi Med Capit...,
  
• Felixbaker Julian Baker Bro...,
  
• Vickie S Reed,
  SVP, Chief Accounting Officer
• Isan Chen,
  EVP, Chief Medical Officer
• Shalini Sharp,
  
• Capital, Llc Boxer Asset Ma...,
  
• Ltd.Lewis Joseph Braslyn,
  
• Capital, Llc Boxer Asset Ma...,
  
• David D. Meek,
  Chief Executive Officer
• Jamie Christensen,
  EVP & Chief Scientific Officer
• John B Moriarty,
  Chief Legal Officer
• Carol Giltner Gallagher,
  
• Alan B. Sandler,
  Chief Medical Officer
• Aaron I. Davis,
  
• Capital, Llc Boxer Asset Ma...,